当代纤维化间质性肺疾病结局:多中心国家队列研究
研究基于加拿大肺纤维化登记队列(CARE-PF)4236例纤维化间质性肺疾病患者,评估当代无移植生存率及基线相关因素,并验证ILD-GAP指数表现。结果显示总体1、3、5年无移植生存率分别为91%、72%、57%,IPF最低而CTD-ILD最高,ILD-GAP具有中等区分度。
要点
- 纤维化ILD总体5年无移植生存率为57%,IPF最低(39%),CTD-ILD最高(70%)。
- 校正后CTD-ILD较IPF的5年生存风险显著更低(HR 0.64,95%CI 0.55-0.76)。
- ILD-GAP指数在1、2、3年的区分度分别为C=0.75、0.74、0.73,属中等。
核心结论
- 在入组锚定的登记队列中,CTD-ILD的无移植生存优于IPF,ILD-GAP提供中等预后准确性。
研究设计与样本
- 前瞻性纳入加拿大肺纤维化登记(CARE-PF)中IPF、fHP、CTD-ILD或uILD患者共4236例,以入组时间为零点。
- 采用Cox比例风险模型评估基线特征与死亡或移植时间的关联,并用Harrell C统计量评估ILD-GAP区分度。
主要发现
- 4236例中IPF占31%、CTD-ILD占40%、fHP占9%、uILD占20%。
- 总体无移植生存率1年为91%、3年为72%、5年为57%。
- IPF无移植生存率最低(1年87%、3年61%、5年39%),CTD-ILD最高(95%、81%、70%)。
- 校正后CTD-ILD较IPF的5年生存风险比为0.64(95%CI 0.55-0.76)。
- ILD-GAP区分度在1年C=0.75、2年C=0.74、3年C=0.73。
临床怎么用
- 可将ILD-GAP指数用于纤维化ILD患者1–3年预后分层,但需知悉其区分度仅为中等。
- 对IPF患者应关注其较低的5年无移植生存率,CTD-ILD患者预后相对较好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: This study determined contemporary transplant-free survival in fibrotic interstitial lung disease (ILD), identified baseline factors associated with death or transplant, and assessed performance of the ILD-GAP (Gender, Age, Physiology) index in a contemporary cohort. METHODS: Patients with idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (fHP), connective tissue disease-associated ILD (CTD-ILD), or unclassifiable ILD (uILD) prospectively enrolled in the Canadian Registry for Pulmonary Fibrosis were included. Transplant-free survival at 1, 3, and 5 years was estimated overall and by subtype using enrollment as time zero. Cox proportional hazards models evaluated associations between patient characteristics and time to death or transplant. ILD-GAP scores were calculated at 1, 2, and 3 years, and discriminability was assessed with Harrell's C statistic. RESULTS: Among 4236 patients with fibrotic ILD enrolled in the Canadian Registry for Pulmonary Fibrosis (CARE-PF), 31% had IPF, 40% CTD-ILD, 9% fHP, and 20% uILD. Overall transplant-free survival was 91% at 1 year, 72% at 3 years, and 57% at 5 years. Survival was lowest in IPF (87%, 61%, 39%) and highest in CTD-ILD (95%, 81%, 70%). Compared with IPF, CTD-ILD was associated with better 5-year survival after adjustment (hazard ratio 0.64 [0.55-0.76]). ILD-GAP showed moderate discrimination at 1 (C = 0.75), 2 (C = 0.74), and 3 years (C = 0.73). CONCLUSION: In this registry cohort anchored at enrollment, CTD-ILD had superior transplant-free survival versus IPF, and ILD-GAP provided moderate prognostic accuracy.
引用
- Pitre T, Ryerson CJ, Ong S, et al. Contemporary Fibrotic Interstitial Lung Disease Outcomes: A Multicentre National Cohort Study. Respirology. 2026. PMID: 42706029. doi:10.1002/resp.70305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。